| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Not Yet Recruiting | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymp NCT07159906 | First Affiliated Hospital of Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HS NCT06839456 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Recruiting | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920 | Rita Assi | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Recruiting | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) NCT06343311 | Estrella Biopharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05967416 | SIRPant Immunotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Ly NCT06097455 | Fundacion Clinic per a la Recerca Biomédica | EARLY_Phase 1 |
| Recruiting | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL NCT06104592 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Unknown | Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Resea NCT06049381 | Ruijin Hospital | — |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Recruiting | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma NCT05826535 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIM NCT05746858 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma NCT05621096 | University of Nebraska | Phase 1 |
| Recruiting | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin' NCT05260957 | Lazaros Lekakis | Phase 2 |
| Unknown | ThisCART19A for B-NHL Relapsed After Auto-CAR T NCT05691153 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Active Not Recruiting | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma NCT05053659 | Paolo Caimi, MD | Phase 1 |
| Enrolling By Invitation | Long-Term Follow-up Study NCT05332054 | Caribou Biosciences, Inc. | — |
| Terminated | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndro NCT04978779 | Vincerx Pharma, Inc. | Phase 1 |
| Unknown | Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non- NCT05420493 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANT NCT04637763 | Caribou Biosciences, Inc. | Phase 1 |
| Recruiting | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refra NCT03938987 | University of Alberta | Phase 1 / Phase 2 |
| Completed | A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity NCT04150913 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Unknown | A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma NCT04923789 | The First Affiliated Hospital of Soochow University | — |
| Unknown | A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma NCT04539444 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) NCT03774654 | Baylor College of Medicine | Phase 1 |
| Completed | Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma NCT05006534 | National Taiwan University Hospital | — |
| Unknown | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma NCT04012892 | Chinese PLA General Hospital | Phase 1 |
| Unknown | Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym NCT03719989 | Seoul National University Hospital | Phase 2 |
| Unknown | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin NCT03778619 | GC Cell Corporation | Phase 1 / Phase 2 |
| Unknown | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma NCT03505944 | Nordic Lymphoma Group | Phase 1 / Phase 2 |
| Unknown | Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma NCT03540303 | Henan Cancer Hospital | Phase 1 |
| Completed | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma NCT03892421 | La Raza Medical Center | Phase 1 / Phase 2 |
| Unknown | CAR-T for R/R B-NHL NCT03196830 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Follow NCT03091933 | Ciusss de L'Est de l'Île de Montréal | Phase 1 / Phase 2 |
| Terminated | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgki NCT02875067 | NYU Langone Health | Phase 1 / Phase 2 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma NCT01811368 | Joseph Tuscano | Phase 2 |
| Completed | Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT NCT04464590 | University Hospital, Brest | — |
| Completed | Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL NCT03042585 | Loyola University | N/A |
| Completed | Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma NCT02099292 | Georg Hess, MD | Phase 2 |